BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

4 Reasons Pfizer Could Be a Value Play You Can't MissBioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufactu